Entrada Therapeutics, Inc.
TRDA
$6.09
-$0.70-10.31%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -97.94% | -65.23% | -10.63% | -55.25% | 421.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -97.94% | -65.23% | -10.63% | -55.25% | 421.16% |
| Cost of Revenue | 18.24% | 12.12% | 18.08% | 40.85% | 21.81% |
| Gross Profit | -157.34% | -137.74% | -70.55% | -154.25% | 870.71% |
| SG&A Expenses | 18.25% | 9.31% | 13.95% | 32.38% | 13.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.24% | 11.42% | 17.11% | 38.71% | 19.73% |
| Operating Income | -187.69% | -203.21% | -219.61% | -254.57% | 427.77% |
| Income Before Tax | -174.28% | -168.50% | -108.04% | -187.98% | 578.35% |
| Income Tax Expenses | -93.55% | -- | -109.98% | 89.31% | -80.08% |
| Earnings from Continuing Operations | -178.32% | -173.84% | 111.85% | -139.57% | 312.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -178.32% | -173.84% | 111.85% | -139.57% | 312.25% |
| EBIT | -187.69% | -203.21% | -219.61% | -254.57% | 427.77% |
| EBITDA | -184.32% | -194.54% | -186.42% | -239.57% | 448.98% |
| EPS Basic | -164.76% | -160.22% | 109.69% | -132.42% | 305.94% |
| Normalized Basic EPS | -161.42% | -155.86% | -106.56% | -172.08% | 564.08% |
| EPS Diluted | -167.27% | -162.12% | 107.17% | -134.31% | 298.26% |
| Normalized Diluted EPS | -163.80% | -158.02% | -106.21% | -175.32% | 546.73% |
| Average Basic Shares Outstanding | 20.94% | 22.62% | 22.40% | 22.08% | 3.07% |
| Average Diluted Shares Outstanding | 16.42% | 18.06% | 29.01% | 16.83% | 7.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |